Inna Shifrin, MD
Geriatric Medicine · Brooklyn, NYNPI 1710967971
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 1,131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Among geriatric medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,131 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$2K
- GSK$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$856
- plus $11K from 54 others
What the payments were for
- Consulting fees$1000%
- Food & beverage$21,23899%
- Education$690%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIVEXTRO$100
How this compares
$21,407 in reported general payments places this provider in the 95th percentile of 400 geriatric medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 249 | $297,030 |
| JardianceEmpagliflozin | 244 | $174,591 |
| EliquisApixaban | 145 | $119,529 |
| ZenpepLipase/Protease/Amylase | 67 | $107,821 |
| VascepaIcosapent Ethyl | 188 | $80,261 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 112 | $74,062 |
| EntrestoSacubitril/Valsartan | 75 | $64,503 |
| OzempicSemaglutide | 63 | $63,271 |
| XareltoRivaroxaban | 74 | $58,130 |
| RybelsusSemaglutide | 42 | $49,243 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 69 | $49,157 |
| FarxigaDapagliflozin Propanediol | 52 | $48,100 |
| XolairOmalizumab | 12 | $32,703 |
| JanuviaSitagliptin Phosphate | 42 | $29,549 |
| CreonLipase/Protease/Amylase | 20 | $24,920 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,184 | $320,107271 claims |
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Spiriva Respimat | $856 | $218,734307 claims |
| PfizerEliquis | $247 | $119,529145 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix, Anoro Ellipta | $1,752 | $113,572232 claims |
| Novo NordiskOzempic, Rybelsus | $715 | $112,514105 claims |
| Aimmune Therapeutics, Inc.Zenpep | $473 | $107,82167 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $2,248 | $106,095159 claims |
| NovartisEntresto | $762 | $64,50375 claims |
| AbbVieCreon, Linzess, Namzaric | $3,030 | $59,80276 claims |
| Johnson & JohnsonXarelto | $309 | $58,13074 claims |
| MerckJanuvia, Janumet Xr | $663 | $37,62256 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $147 | $22,49339 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 geriatric medicine providers in New York.
Other geriatric medicine in Brooklyn
- Wen DombrowskiBrooklyn$45K
- Sergey GenkinBrooklyn$10K
- Diana LevinaBrooklyn$9K
- Faina KoganBrooklyn$7K
- William PutmanBrooklyn$6K
- Roberto RobinsonBrooklyn$6K
- Nathalia IdelevitchBrooklyn$5K
- Stefano FrancoBrooklyn$3K
- Larissa GoldBrooklyn$3K
- Howard OrkinBrooklyn$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.